Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Share-based Compensation (2017 - 2026)

Kiniksa Pharmaceuticals International filings provide 6 years of Share-based Compensation readings, the most recent being $10.1 million for Q1 2026.

  • On a quarterly basis, Share-based Compensation rose 29.79% to $10.1 million in Q1 2026 year-over-year; TTM through Mar 2026 was $39.3 million, a 25.86% increase, with the full-year FY2025 number at $37.0 million, up 20.56% from a year prior.
  • Share-based Compensation hit $10.1 million in Q1 2026 for Kiniksa Pharmaceuticals International, down from $10.2 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $10.2 million in Q4 2025 to a low of $6.0 million in Q1 2022.
  • Median Share-based Compensation over the past 5 years was $7.4 million (2024), compared with a mean of $7.6 million.
  • Biggest five-year swings in Share-based Compensation: fell 15.37% in 2022 and later rose 29.79% in 2026.
  • Kiniksa Pharmaceuticals International's Share-based Compensation stood at $6.4 million in 2022, then grew by 21.99% to $7.8 million in 2023, then increased by 6.75% to $8.3 million in 2024, then grew by 23.34% to $10.2 million in 2025, then decreased by 1.75% to $10.1 million in 2026.
  • The last three reported values for Share-based Compensation were $10.1 million (Q1 2026), $10.2 million (Q4 2025), and $10.1 million (Q3 2025) per Business Quant data.